Radiopharm Theranostics (Radiopharm Theranostics) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Radiopharm Theranostics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Radiopharm Theranostics's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Radiopharm Theranostics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Radiopharm Theranostics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics LT-Debt-to-Total-Asset Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

LT-Debt-to-Total-Asset

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	-	-	-	-	-

Radiopharm Theranostics LT-Debt-to-Total-Asset Calculation

Radiopharm Theranostics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	0	/	50.302
	=	0.00

Radiopharm Theranostics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	42.365
	=

Radiopharm Theranostics (OTCPK:RDPTF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Radiopharm Theranostics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022